Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Sci Transl Med. 2011 Sep 28;3(102):102mr2. doi: 10.1126/scitranslmed.3002804.

Translating glutamate: from pathophysiology to treatment.

Author information

  • 1Translational Schizophrenia Research Center, Nathan Kline Institute/Columbia University College of Physicians and Surgeons, New York, NY 10032, USA. javitt@nki.rfmh.org

Abstract

The neurotransmitter glutamate is the primary excitatory neurotransmitter in mammalian brain and is responsible for most corticocortical and corticofugal neurotransmission. Disturbances in glutamatergic function have been implicated in the pathophysiology of several neuropsychiatric disorders-including schizophrenia, drug abuse and addiction, autism, and depression-that were until recently poorly understood. Nevertheless, improvements in basic information regarding these disorders have yet to translate into Food and Drug Administration-approved treatments. Barriers to translation include the need not only for improved compounds but also for improved biomarkers sensitive to both structural and functional target engagement and for improved translational models. Overcoming these barriers will require unique collaborative arrangements between pharma, government, and academia. Here, we review a recent Institute of Medicine-sponsored meeting, highlighting advances in glutamatergic theories of neuropsychiatric illness as well as remaining barriers to treatment development.

PMID:
21957170
[PubMed - indexed for MEDLINE]
PMCID:
PMC3273336
Free PMC Article

Images from this publication.See all images (5)Free text

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk